Hiroshi Sakamoto

Summary

Affiliation: Chugai Pharmaceutical Co
Country: Japan

Publications

  1. ncbi Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Nat Chem Biol 1:333-7. 2005
  2. ncbi CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Cancer Cell 19:679-90. 2011
  3. ncbi Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem 20:1271-80. 2012
  4. ncbi 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    J Med Chem 54:6286-94. 2011
  5. ncbi Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors
    Takashi Chiba
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 22:7486-9. 2012
  6. ncbi Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
    Hiroki Nishii
    Department of Chemistry Research 2, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 20:1405-9. 2010
  7. ncbi Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3788-93. 2011

Collaborators

  • Takaaki Miura
  • Michinori Kohara
  • Yoshiyuki Ono
  • Takashi Emura
  • Kazutomo Kinoshita
  • Takamitsu Kobayashi
  • Jun Ohwada
  • Nobuhiro Oikawa
  • Noriyuki Furuichi
  • Kohsuke Asoh
  • Hatsuo Kawada
  • Takuo Tsukuda
  • Toshiyuki Tsukaguchi
  • Toshiya Ito
  • Takashi Chiba
  • Sousuke Hara
  • Takuho Miyagi
  • Kenji Takanashi
  • Takaaki A Fukami
  • Hiroshi Koyano
  • Kenji Morikami
  • Hiroki Nishii
  • Kazuhiro Ohara
  • Machiko Irie
  • Woo Sang Hong
  • Min Jeong Park
  • Shota Tanaka
  • Kazuo Hattori
  • Kwangseok Ko

Detail Information

Publications7

  1. ncbi Host sphingolipid biosynthesis as a target for hepatitis C virus therapy
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Nat Chem Biol 1:333-7. 2005
    ..Thus, NA255 is a new anti-HCV replication inhibitor that targets host lipid rafts, suggesting that inhibition of sphingolipid metabolism may provide a new therapeutic strategy for treatment of HCV infection...
  2. ncbi CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant
    Hiroshi Sakamoto
    Kamakura Research Laboratories, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Cancer Cell 19:679-90. 2011
    ..Our results support the potential for clinical evaluation of CH5424802 for the treatment of patients with ALK-driven tumors...
  3. ncbi Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem 20:1271-80. 2012
    ..In this work, we optimized the side-chains and identified highly selective, orally active and potent ALK inhibitor CH5424802 (18a) as the clinical candidate...
  4. ncbi 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    J Med Chem 54:6286-94. 2011
    ..8 nM. The compound also displayed significant antitumor efficacy in an established ALK fusion gene-positive anaplastic large-cell lymphoma (ALCL) xenograft model in mice without body weight loss...
  5. ncbi Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors
    Takashi Chiba
    Research Division, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 22:7486-9. 2012
    ....
  6. ncbi Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
    Hiroki Nishii
    Department of Chemistry Research 2, Chugai Pharmaceutical Co, Ltd, 200 Kajiwara, Kamakura, Kanagawa 247 8530, Japan
    Bioorg Med Chem Lett 20:1405-9. 2010
    ....
  7. ncbi Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
    Kazutomo Kinoshita
    Kamakura Research Laboratories, Chugai Pharmaceutical Co Ltd, Kamakura, Kanagawa, Japan
    Bioorg Med Chem Lett 21:3788-93. 2011
    ..Among them, compound 27 showed strong cytotoxicity against KARPAS-299 with an IC(50) value of 21 nM and significant antitumor efficacy in ALK fusion-positive blood and solid cancer xenograft models in mice without body weight loss...